US FDA Staff Recommend Psych Warnings for Roche Holding AG and GlaxoSmithKline Flu Drugs

WASHINGTON, Nov 23 (Reuters) - U.S. Food and Drug Administration staffers recommended new warnings about psychiatric side effects seen in some patients taking Roche Holding AG's (ROG.VX: Quote, Profile, Research) Tamiflu and GlaxoSmithKline Plc's (GSK.L: Quote, Profile, Research) Relenza, according to documents released on Friday.

Back to news